These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30148825)

  • 1. Immunotherapy in the adjuvant setting for high-risk melanoma.
    Weber JS
    Clin Adv Hematol Oncol; 2018 Aug; 16(8):546-548. PubMed ID: 30148825
    [No Abstract]   [Full Text] [Related]  

  • 2. Noninterferon-based adjuvant therapy for high-risk melanoma.
    Spitler LE
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):547-62. PubMed ID: 12382523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma adjuvant therapy.
    Tarhini AA; Thalanayar PM
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic manual of malignant melanoma].
    Moroi Y
    Fukuoka Igaku Zasshi; 2009 Feb; 100(2):51-8. PubMed ID: 19455975
    [No Abstract]   [Full Text] [Related]  

  • 5. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.
    McKean MA; Amaria RN
    Cancer Treat Rev; 2018 Nov; 70():144-153. PubMed ID: 30195813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapies for malignant melanoma.
    Olofsson Bagge R; Ny L
    Br J Surg; 2016 Aug; 103(9):1095-6. PubMed ID: 27246114
    [No Abstract]   [Full Text] [Related]  

  • 7. Malignant mucosal melanoma in the olfactory cleft of a 10-year-old child.
    Mun SJ; Jung HY; Frolova A; Park KD; Rhee CS
    Auris Nasus Larynx; 2013 Apr; 40(2):235-8. PubMed ID: 22677526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma.
    Chiarion-Sileni V; Guida M; Romanini A; Bernengo MG; Ascierto P; Queirolo P; Mandalà M; Maio M; Ferraresi V; Stanganelli I; Testori A; Ridolfi R
    Dermatology; 2013; 226 Suppl 1():22-7. PubMed ID: 23736267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma. A commentary.
    Nathanson L
    Cancer; 2001 Mar; 91(5):881-8. PubMed ID: 11251939
    [No Abstract]   [Full Text] [Related]  

  • 10. The current EORTC Melanoma Cooperative Group adjuvant trial programme on malignant melanoma: prognosis versus efficacy, toxicity and costs.
    Eggermont AM
    Melanoma Res; 1997 Aug; 7 Suppl 2():S127-31. PubMed ID: 9578428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?
    Postow MA
    Clin Adv Hematol Oncol; 2018 May; 16(5):353-355. PubMed ID: 29851931
    [No Abstract]   [Full Text] [Related]  

  • 12. [2nd revised consensus skin melanoma. De Nederlandse Melanoom Werkgroep].
    Kroon BB; Bergman W; Coebergh JW; Ruiter DJ
    Ned Tijdschr Geneeskd; 1997 Oct; 141(42):2015-9. PubMed ID: 9550753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis, treatment and follow-up of primary malignant skin melanoma].
    Ketterer R
    Rev Med Suisse Romande; 1995 Oct; 115(10):753-7. PubMed ID: 7501925
    [No Abstract]   [Full Text] [Related]  

  • 14. [News on melanoma from the 2010 Dermatology Days in Paris].
    Boulinguez S
    Ann Dermatol Venereol; 2011 May; 138(5 Suppl 1):H16-20. PubMed ID: 21703460
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adjuvant and palliative therapy of melanoma. Current status].
    Tilgen W
    Chirurg; 1994 Mar; 65(3):153-63. PubMed ID: 7514966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of high dose chemoimmunotherapy after surgery on the overall and disease-free survivals in advanced stage malignant melanoma.
    Bilgin Ç; Çetinkünar S; Bilgen K; Celep B; Tokgöz S; Sözen S; Karaca T; Özer S; Tunç G
    Ann Ital Chir; 2012; 83(6):529-33. PubMed ID: 23027639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug clinics. How I treat cutaneous melanoma].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 1998 Jan; 53(1):4-6. PubMed ID: 9555173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adjuvant therapy of malignant melanoma].
    Franke W; Neumann NJ; Ruzicka T; Schulte KW
    Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
    Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
    Melanoma Res; 2008 Apr; 18(2):152-60. PubMed ID: 18337653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.